Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;26(6):1442-4.
doi: 10.1038/leu.2011.375. Epub 2012 Jan 13.

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

J A Woyach, G Lozanski, A S Ruppert, A Lozanski, K A Blum, J A Jones, J M Flynn, A J Johnson, M R Grever, N A Heerema, J C Byrd

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

J A Woyach et al. Leukemia. 2012 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curves showing PFS and OS for patients treated with flavopiridol stratified by cytogenetic status and karyotypic complexity. PFS (1a) and OS (1b) are not significantly different among patients with del(17p13.1), del(11q22.3), or those without these high-risk markers. Among all patients, the presence of complex karyotype did not impact PFS (1c), however, in the subset of patients with del(17p13.1) (1d), patients with complex karyotype had inferior PFS. Complex karyotype was also significantly associated with inferior OS among all patients(1e).
See this image and copyright information in PMC

References

    1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 28;343(26):1910–1916. - PubMed
    1. Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D, Krober A, Kienle D, Lichter P, Dohner H. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007 Sep;92(9):1242–1245. - PubMed
    1. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumer RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006 Oct 1;24(28):4634–4641. - PubMed
    1. Juliusson G, Robert KH, Ost A, Friberg K, Biberfeld P, Nilsson B, Zech L, Gahrton G. Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. Blood. 1985 Jan;65(1):134–141. - PubMed
    1. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006 Jan 20;24(3):437–443. - PubMed

Publication types

MeSH terms